BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Key Stats

• Today's Range: $8.70 to $9.07
• 50-Day Range: $6.65 to $9.60
• 52-Week Range: $4.66 to $9.90
• Volume: 11,508 shs
• Average Volume: 16,520 shs
• Market Capitalization: $143.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Buy

BHST Stock Analysis - Frequently Asked Questions

How have BHST shares performed this year?

BioHarvest Sciences' stock was trading at $6.18 at the beginning of 2025. Since then, BHST stock has increased by 41.3% and is now trading at $8.73.

How were BioHarvest Sciences' earnings last quarter?

BioHarvest Sciences Inc. (NASDAQ:BHST) posted its quarterly earnings data on Monday, August, 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.04. The firm had revenue of $8.52 million for the quarter, compared to analyst estimates of $8.53 million. BioHarvest Sciences had a negative trailing twelve-month return on equity of 11,357.84% and a negative net margin of 39.95%.
Read the conference call transcript.

Who are BioHarvest Sciences' major shareholders?

Top institutional investors of BioHarvest Sciences include Magnus Financial Group LLC (0.43%) and True North Advisors LLC (0.13%).

How do I buy shares of BioHarvest Sciences?

Shares of BHST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/11/2025
• Today: 8/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioHarvest Sciences: $13.67
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +56.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.91 million
• Net Margins: -39.95%
• Pretax Margin: -39.67%
• Return on Equity: -11,357.84%
• Return on Assets: -39.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 5.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -33.58

Miscellaneous

• Outstanding Shares: 16,420,000
• Free Float: N/A
• Market Cap: $143.35 million
• Optionable: N/A
• Beta: 0.68